Current guidelines recommend monitoring of high risk groups (e.g. primarily those with cirrhosis) with regular ultrasound scanning and alpha-fetoprotein (AFP) levels, which is the only biomarker approved for surveillance [70]. Here, AFP is linked to Cirrhosis.